Therapeutic Effects of Neuroactive Drugs on Hypothalamo-Pituitary in Man

  • P. J. Trainer
  • A. Grossman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 274)


The treatment of endocrine disorders by neuropharmacological manipulation is a therapeutic field that has only began to be exploited in the last twenty years, and continues to evolve rapidly. In 1947, it was first suggested by Green and Harris (1) that hypothalamic substances regulated hormone secretion from the anterior pituitary. Corticotropin-releasing factor was the first of these substances to be identified in a bioassay system, while in 1982 the most recent hypothalamic peptide, growth hormone releasing hormone (GHRH), was sequenced. Paralleling the identification of the hypothalamic peptides has been progress in understanding the complex interactions of the innervation of the hypothalamus. With this knowledge, and the concomitant availability of biosynthetic hypothalamic peptides, modulation of the secretion of prolactin, growth hormone (GH) and adrenocorticotropin by manipulation of the hypothalamic-pituitary axis has resulted in major therapeutic advances. This chapter will confine itself to the drugs relevant to these hormones, but excludes analogues of the hypothalamic peptides such as octreotide and the GnRH superagonists.


Growth Hormone Dopamine Agonist Growth Hormone Release Hormone Sodium Valproate Exogenous Growth Hormone 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Green, J.D., and G.W. Harris, The neurovascular line between the neurohypophysis and adenohypophysis, J Endocrinol 5: 136–146, 1947.PubMedCrossRefGoogle Scholar
  2. 2.
    Frantz, A., and D.L. Kleinberg, Prolactin: evidence that it is separate from growth hormone in human blood, Science 170: 745–747, 1972.CrossRefGoogle Scholar
  3. 3.
    Turner, T.H., J.C. Cookson, J.A.H. Wass, P.L. Drury, PA. Price, and G.M. Besser, Psychotic reactions during treatment of pituitary tumours with dopamine agonists, Br Med J 289: 1101–1103, 1984.CrossRefGoogle Scholar
  4. 4.
    Besser, G.M., L. Parke, C.R.W. Edwards, I.A. Forsyth, and A.S. McNeilly, Galactorrhoea: successful treatment with reduction of plasma prolactin levels by bromergocryptine, Br Med J 3: 669–672, 1972.PubMedCrossRefGoogle Scholar
  5. 5.
    Besser, G., Medical management of prolactinomas, In J.R. Givens (ed) Hormone-Secreting Pituitary Tumours ,Year Book Medical Publisher, Chicago, pp. 255–273 1982.Google Scholar
  6. 6.
    Ciccarelli, E., E. Mazza, E. Ghigo, F. Guidoni, A. Barbaeris, F. Massara, and F. Camanni, Longterm treatment with oral single administration of bromocriptine in patients with hyperprolactinaemia, J Endocrinol Invest 10: 51–53, 1987.PubMedGoogle Scholar
  7. 7.
    Wass, J.A.H., PJA. Moult, M.O. Thorner, J.E. Dacie, M. Charlesworth, A.E. Jones, and G.M. Besser, Reduction in pituitary tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy, Lancet 2: 66–69, 1979.PubMedCrossRefGoogle Scholar
  8. 8.
    Thorner, M.O., G.R.W. Edwards, M. Charlesworth, J.E. Dacie, P.J.A. Moult, L.H. Rees, A.E. Jones and G.M. Besser, Pregnancy in patients presenting with hyperprolactinaemia, Br Med J 2:771–774 ,1979.PubMedCrossRefGoogle Scholar
  9. 9.
    Griffith, R.W., I. Turkalji, and P. Braun, Outcome of pregnancy in mothers taking bromocriptine, Br J Clin Pharmacol 5: 227–231, 1978.PubMedGoogle Scholar
  10. 10.
    Del Pozo, E., K. Schulter, E. Nuesch, J. Rosenthaler, and L. Kerp, Pharmokinetics of a long-acting bromocriptine preparation (Parlodel LAR) and its effect on release of prolactin and growth hormone, Eur J Clin Pharmacol 29: 615–618, 1986.PubMedCrossRefGoogle Scholar
  11. 11.
    Grossman, A., J.A.H. Wass, and M. Besser, The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine, Acta Endocrinol 116: 275–281,1987.PubMedGoogle Scholar
  12. 12.
    Grossman, A., R. Ross, J.A.H. Wass, and G.M. Besser, Depot-bromocriptine treatment for prolactinomas and acromegaly, Clin Endocrinol 24: 231–238, 1986.CrossRefGoogle Scholar
  13. 13.
    Franks, S., P.M. Horrocks, S.S. Lynch, W.W. Butt, and D.R. London, Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia, Br Med J 286: 1177–1179, 1983.CrossRefGoogle Scholar
  14. 14.
    Kleinberg D.L., A.E. Boyd, S. Wardlaw, A.G. Frantz, A. George, N. Bryan, S. Hilal, J. Greising, D. Hamilton, T. Seltzer, and C.J. Sommers, Pergolide for the treatment of pituitary tumours secreting prolactin or growth hormone, N Engl J Med 309: 704–709, 1983.PubMedCrossRefGoogle Scholar
  15. 15.
    Grossman, A., P.M.G. Bouloux, R. Loneragan, L.H. Rees, J.A.H. Wass, and G.M. Besser, Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia, Clin Endocrinol 22: 611–616, 1985.CrossRefGoogle Scholar
  16. 16.
    Horoski, R., and H. Wachtel, Direct dopamine action of lisuride hydrogen maleate, an ergot derivative, in mice, Eur J Pharmacol 36: 373–383, 1976.CrossRefGoogle Scholar
  17. 17.
    Votava, Z., and I. Lamplova, Antiserotonin activity of some ergolenyn and isoergolenyn derivatives in comparison with LSD and the influence of monoamine inhibiton of the serotonin effect, In E. Roshlin (ed) Neuropsychopharmacology II Elsevier/North, Amsterdam, pp. 68–73, 1961.Google Scholar
  18. 18.
    Bouloux, P.M.G., P.J.A. Moult, G.M. Besser, and A. Grossman, Clinical evaluation of lysuride in the management of hyperprolactinaemia, Br Med J 294: 1323–1324, 1987.CrossRefGoogle Scholar
  19. 19.
    Ciccarelli, E., R. Touzel, M. Besser, and A. Grossman, Terguride -a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine, Fertil Steril 49(4): 589–594, 1988.PubMedGoogle Scholar
  20. 20.
    Potirolli, A.E., L. Cammelli, P. Baroldi, and G. Pozza, Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, and extremely long-acting dopaminergic drug, J Clin Endocrinol Metab 65: 1057–1059, 1987.CrossRefGoogle Scholar
  21. 21.
    Ferrari, C., C. Barberi, R. Caldara, M. Mucci, F. Codecasa, A. Paracchi, C. Romano, M. Boghen, and A. Dubini, Long-lasting prolactin lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients, J Clin Endocrinol Metab 63: 941–945, 1986.PubMedCrossRefGoogle Scholar
  22. 22.
    Gaillard, R.C., K. Abeywickrama, J. Brownell, and A.F. Muller, Specific effect of CV 205-502, a potent nonergot dopamine agonist, during a combined anterior pituitary function test, J Clin Endocrinol Metab 68: 329–335, 1989.PubMedCrossRefGoogle Scholar
  23. 23.
    Guillemin, R., P. Brazeau, P. Boehlen, F. Esch, N. Ling, and W.B. Wehrenberg, Growth hormone-releasing factor from a human pancreas that caused acromegaly, Science 218: 585–587, 1982.PubMedCrossRefGoogle Scholar
  24. 24.
    Rivier, J., J. Spiess, M. Thorner, and W. Vale, Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour, Nature 300: 276–278, 1982.PubMedCrossRefGoogle Scholar
  25. 25.
    Vance, M.L., D.L. Kaiser, LA. Frohman, J. Rivier, W.W. Vale, and M.O. Thorner, Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone stimulated GH secretion in normal men, J Clin Endocrinol Metab 64:1136–1141, 1987.PubMedCrossRefGoogle Scholar
  26. 26.
    Delitala, G., M. Palermo, R. Ross, D. Coy, M. Besser, and A. Grossman, Dopaminergic and cholinergic influences on the growth hormone response to growth hormone-releasing hormone in man, Neuroendocrinology 45: 243–247,1987.PubMedCrossRefGoogle Scholar
  27. 27.
    Chihara, K., H. Kodama, H. Kaji, T. Kita, Y. Kashio, Y. Okimura, H. Abe, and T. Fujita, Augmentation by propranolol of growth hormone-releasing hormone-(l-44)-NH2-induced growth hormone release in normal short and normal children, J Clin Endocrinol Metab 61: 229–233, 1985.PubMedCrossRefGoogle Scholar
  28. 28.
    Grossman, A., K. Weerasuriya, S. Al-Damluju, P. Turner, and G.M. Besser, Alpha 2-adrenoceptor agonists stimulate growth hormone secretion but have no effects on plasma Cortisol under basal conditions, Horm Res 25: 65–71, 1987.PubMedCrossRefGoogle Scholar
  29. 29.
    Tsagarakis, S., G. Feng, L.H. Rees, G.M. Besser, and A. Grossman, Stimulation of alpha-adrenoceptors facilitates the release of growth hormone-releasing hormone from rat hypothalamus in vitro, J Neuroendocrinology 1: 129–133, 1989.CrossRefGoogle Scholar
  30. 30.
    Locatelli, V., A. Torsello, M. Redaelli, E. Ghigo, F. Massara, and E.E. Müller, Cholinergic agonists and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin, J Endocrinol 111: 271–278, 1986.PubMedCrossRefGoogle Scholar
  31. 31.
    Ross, R.J.M., S. Tsagarakis, A. Grossman, L. Nhagafoong, R.J. Touzel, L.H. Rees, and G.M. Besser, GH feedback occurs through modulation of hypothalmaic somatostatin under cholinergic control: studies with pyridostigmine and GHRH, Clin Endocrinol 27: 727–733, 1987.CrossRefGoogle Scholar
  32. 32.
    Thorner, M.O., J. Reschke, J. Chitwood, A.D. Rogol, R. Furlanetto, J. Rivier, W. Vale, and R.M. Blizzard, Acceleration of growth in two children treated with human growth hormone-releasing factor, N Engl J Med 312: 4–9, 1985.PubMedCrossRefGoogle Scholar
  33. 33.
    Ross, R.J.M., S. Tsagarakis, A. Grossman, MA. Preece, C. Rodda, P.S.W. Davies, L.H. Rees, M.O. Savage, and G.M. Besser, Treatment of growth-hormone deficiency with growth hormone-releasing hormone, Lancet 1: 5–8, 1987.PubMedCrossRefGoogle Scholar
  34. 34.
    Low, L.C.A., C. Wang, P.T. Cheung, P. Ho, K.S.L. Lam, R.T.T. Young, C. Yeung, and N. Ling, Long term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency, J Clin Endocrinol Metab 66: 611–617, 1988.PubMedCrossRefGoogle Scholar
  35. 35.
    Brain C., P.C. Hindmarsh, C.G.D. Brooks, and D.R. Matthews, Continuous subcutaneous growth hormone releasing factor analogue augments growth hormone secretion in normal male subjects with no desensitization of the somatotroph, Clin Endocrinol 28: 543–549, 1988.CrossRefGoogle Scholar
  36. 36.
    Pintor, C, S.G. Cella, R. Corda, V. Locatelli, R. Puggioni, S. Loche, and E.E. Müller, Clonidine accelerates growth in children with impaired growth hormone secretion, Lancet 1: 1482–1484, 1985.PubMedCrossRefGoogle Scholar
  37. 37.
    Castro-Magnana, M., M. Angulo, B. Fuentes, M.E. Catelar, A. Canas, and B. Espinoza, Effect of prolonged Clonidine administration on growth hormone concentrations and rate of linear growth in children with constitutional growth delay, J Pediatr 109: 784–787, 1986.CrossRefGoogle Scholar
  38. 38.
    Pescovitz, O.H., and E. Tan, Lack of benefit of Clonidine treatment for short stature in a double-blind, placebo-controlled trial, Lancet 2: 874–877, 1988.PubMedCrossRefGoogle Scholar
  39. Dayanithi, G., and F. Antoni, Atriopeptins are potent inhibitors of corticotropin secretion by anterior pituitary cells in vitro: involvement of the -ANF receptor domain of membrane-bound cuanylate cyclase, Biochem Biophys Res Commun ,In Press.Google Scholar
  40. 40.
    Al-Damluji, S., S. Tomlin, L. Perry, P. Bouloux, A. Grossman, L.H. Rees and G. Besser, Alpha adrenoceptor stimulation of ACTH secretion by a specific central mechanism in man, J Endocrinol 104: 40, Abstract #48, 1985.Google Scholar
  41. 41.
    Tsagarakis, S., J.M.P. Holly, L.H. Rees, G.M. Besser, and A. Grossman, Acetylcholine and norepinephrine stimulate the release of corticotrophin-releasing factor-41 from the rat hypothalamus in vivo, Endocrinology 123: 1962–1969, 1988.PubMedCrossRefGoogle Scholar
  42. 42.
    Mamplan, T., J. Blake Tyrell, and C.B. Wilson, Transsphenoidal microsurgery for Cushing’s disease, Ann Int Med 109: 487–493, 1988.Google Scholar
  43. Howlett, T., P. Plowman, J. Wass, L. Rees, A. Jones, and G. Besser, Megavoltage pituitary irradiation in the management of Cushing’s disease and Nelson’s syndrome, long-term follow-up, Clin Endocrinol ,In Press.Google Scholar
  44. 44.
    Lamberts, S.W.J., S A. DeLange, and S.Z. Stefanko, Adrenocorticotrophin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing’s disease: differences in the regulation of hormone secretion, J Clin Endocrinol Metab 54: 286–291, 1982.PubMedCrossRefGoogle Scholar
  45. 45.
    Hale, A.C., P.J. Coates, I. Doniach, TA. Howlett, A. Grossman, L.H. Rees, and G.M. Besser, A bromocriptine-responsive corticotroph adenoma secreting α-MSH in a patient with Cushing’s disease, Clin Endo 28: 215–223, 1988.CrossRefGoogle Scholar
  46. 46.
    Scott, R., E.A. Espinger, and R.A. Donald, Cyproheptadine for Cushing’s disease, N Engl J Med 296 57–58, 1977.PubMedGoogle Scholar
  47. 47.
    Jones, M.T., E.W. Hillhouse, and J. Burden, Effect of various putative neurotransmitters on the release of corticotrophin-releasing hormone from the rat hypothalamus in vitro-a model of the neurotransmitters involved, J Endocrinol 69: 1–10, 1976.PubMedCrossRefGoogle Scholar
  48. 48.
    Godin, Y., L. Heiner, J. Mark, and P. Madel, Effect of di-n-propyl-acetate anticonvulsant compound on GABA metabolism, J Neurochem 16: 869–873,1969.PubMedCrossRefGoogle Scholar
  49. 49.
    Dornhurst, A., J.S. Jenkins, S.W.J. Lamberts, R.R. Abraham, A.V. Wynn, U. Beckford, B. Gillham, and M.T. Jones, The evaluation of sodium valproate in the treatment of Nelson’s syndrome, J Clin Endocrinol Metab 56: 985–991, 1983.CrossRefGoogle Scholar
  50. 50.
    Koppeschaar, H.P.F., R.J.M. Croughs, J.H.H. Thijssen, and F. Schwarz, Sodium valproate and cyproheptadine may independently induce a remission in the patient with Cushing’s disease, Acta Endocrinol 104: 160–163, 1983.PubMedGoogle Scholar
  51. 51.
    Stafford, P., P. Kopelman, K. Davidson, T. Loughlin, A. White, L. Reese, G. Besser, D. Coy, and A. Grossman, The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects, Clin Endocrinol 30: 651–666, 1989.CrossRefGoogle Scholar
  52. 52.
    Avgerinos, P.C., L.K. Nieman, E.H. Oldfield, T. Loughlin, K.M. Barnes, D.L. Loriaux, and G.B. Cutler, Jr., The effect of pulsatile corticotrophin releasing hormone administration on the adrenal insufficiency that follows cure of Cushing’s disease, J Clin Endocrinol Metab 68: 912–916, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • P. J. Trainer
    • 1
  • A. Grossman
    • 1
  1. 1.Department of EndocrinologySt. Bartholomew’s HospitalWest Smithfield, LondonUK

Personalised recommendations